BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 15113061)

  • 1. Clinical impact of Resovist-enhanced MRI: results of an Italian multicenter trial.
    Lencioni R; Bartolozzi C;
    Eur Radiol; 2004 Jan; 14 Suppl 1():C10. PubMed ID: 15113061
    [No Abstract]   [Full Text] [Related]  

  • 2. Preoperative evaluation of malignant liver tumors: comparison of unenhanced and SPIO (Resovist)-enhanced MR imaging with biphasic CTAP and intraoperative US.
    Vogl TJ; Schwarz W; Blume S; Pietsch M; Shamsi K; Franz M; Lobeck H; Balzer T; del Tredici K; Neuhaus P; Felix R; Hammerstingl RM
    Eur Radiol; 2003 Feb; 13(2):262-72. PubMed ID: 12598989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative patient work-up: Resovist-enhanced MRI vs. multislice CT--preliminary results of an ongoing study.
    Heinz-Peer G
    Eur Radiol; 2004 Jan; 14 Suppl 1():C11-2. PubMed ID: 15113062
    [No Abstract]   [Full Text] [Related]  

  • 4. [MR contrast agent: resovist (SH U 555A)].
    Nakajima H; Ichikawa T
    Nihon Rinsho; 2001 Oct; 59 Suppl 6():328-32. PubMed ID: 11761967
    [No Abstract]   [Full Text] [Related]  

  • 5. Usefulness of combining sequentially acquired gadobenate dimeglumine-enhanced magnetic resonance imaging and resovist-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: comparison with computed tomography hepatic arteriography and computed tomography arterioportography using 16-slice multidetector computed tomography.
    Kim YK; Kwak HS; Han YM; Kim CS
    J Comput Assist Tomogr; 2007; 31(5):702-11. PubMed ID: 17895780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience with Resovist in gastroenterologic radiology and intervention.
    Vogl TJ; Schwarz W; Marquart F; Parmentier S; Götz B; Thalhammer A; Hammerstingl R
    Eur Radiol; 2004 Jan; 14 Suppl 1():C7-9. PubMed ID: 15113060
    [No Abstract]   [Full Text] [Related]  

  • 7. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advantages and differences of Resovist towards Gadolinium contrast in MRI with focus on metastatic liver lesions.
    Reimer P; Balzer T
    Eur Radiol; 2004 Jan; 14 Suppl 1():C4. PubMed ID: 15113058
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical management of hepatic malignancies: ferucarbotran-enhanced magnetic resonance imaging versus contrast-enhanced spiral computed tomography.
    Lencioni R; Della Pina C; Bruix J; Majno P; Grazioli L; Morana G; Filippone A; Laghi A; Bartolozzi C
    Dig Dis Sci; 2005 Mar; 50(3):533-7. PubMed ID: 15810637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Differential diagnosis of focal liver lesions using contrast-enhanced MRI with SHU 555 A in comparison with unenhanced MRI and multidetector spiral-CT].
    Jung G; Poll L; Cohnen M; Saleh A; Vogler H; Wettstein M; Willers R; Mödder U; Koch JA
    Rofo; 2005 Nov; 177(11):1571-7. PubMed ID: 16302139
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contrast-enhanced MRI of focal liver lesions: differentiation and detection of primary and secondary liver lesions using Resovist-enhanced versus gadolinium-enhanced MRI in the same patient.
    Hammerstingl R; Vogl TJ; Schwarz W; Kümmel S; Balzer T; Neuhaus P; Felix R
    Acad Radiol; 1998 Apr; 5 Suppl 1():S75-9; discussion S93-4. PubMed ID: 9561049
    [No Abstract]   [Full Text] [Related]  

  • 12. Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.
    Ichikawa T; Saito K; Yoshioka N; Tanimoto A; Gokan T; Takehara Y; Kamura T; Gabata T; Murakami T; Ito K; Hirohashi S; Nishie A; Saito Y; Onaya H; Kuwatsuru R; Morimoto A; Ueda K; Kurauchi M; Breuer J
    Invest Radiol; 2010 Mar; 45(3):133-41. PubMed ID: 20098330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resovist for imaging of hepatocellular carcinoma in the cirrhotic liver.
    Weishaupt D; Willmann JK; Lutz AM; Marincek B
    Eur Radiol; 2004 Jan; 14 Suppl 1():C5-6. PubMed ID: 15113059
    [No Abstract]   [Full Text] [Related]  

  • 14. Diagnosis of liver metastases from colorectal adenocarcinoma. Comparison of spiral-CTAP combined with intravenous contrast-enhanced spiral-CT and SPIO-enhanced MR combined with plain MR imaging.
    Strotzer M; Gmeinwieser J; Schmidt J; Fellner C; Seitz J; Albrich H; Zirngibl H; Feuerbach S
    Acta Radiol; 1997 Nov; 38(6):986-92. PubMed ID: 9394654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health economic evaluation of ferucarbotran-enhanced MRI in the diagnosis of liver metastases in colorectal cancer patients.
    Annemans L; Lencioni R; Warie H; Bartolozzi C; Ciceri M; Müller U
    Int J Colorectal Dis; 2008 Jan; 23(1):77-83. PubMed ID: 17912536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superparamagnetic iron oxide-enhanced liver MRI with SHU 555 A (RESOVIST): New protocol infusion to improve arterial phase evaluation--a prospective study.
    Grazioli L; Bondioni MP; Romanini L; Frittoli B; Gambarini S; Donato F; Santoro L; Colagrande S
    J Magn Reson Imaging; 2009 Mar; 29(3):607-16. PubMed ID: 19243056
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ferumoxide-enhanced magnetic resonance imaging techniques in pre-operative assessment for colorectal liver metastases.
    van Etten B; van der Sijp J; Kruyt R; Oudkerk M; van der Holt B; Wiggers T
    Eur J Surg Oncol; 2002 Sep; 28(6):645-51. PubMed ID: 12359202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results of a multicenter phase II clinical trial with a susceptibility contrast medium for magnetic resonance imaging of the liver.
    Balzer T; Carter EC; Shamsi K; Niendorf HP
    Acad Radiol; 1996 Aug; 3 Suppl 2():S417-9. PubMed ID: 8796619
    [No Abstract]   [Full Text] [Related]  

  • 19. [The characterization value of feridex-enhanced MR imaging for focal hepatic lesions in reference to their histological pathology].
    Yang HF; Zhou XP; Yu JQ; Song B; Guang YS; Zhang HY; Chen X
    Zhonghua Gan Zang Bing Za Zhi; 2005 Jul; 13(7):548-50. PubMed ID: 16042902
    [No Abstract]   [Full Text] [Related]  

  • 20. [T1-weighted dynamic MRI with new superparamagnetic iron oxide particles (Resovist): results of a phantom study as well as 25 patients].
    Müller M; Reimer P; Wiedermann D; Allkemper T; Marx C; Tombach B; Rummeny EJ; Shamsi K; Balzer T; Peters PE
    Rofo; 1998 Mar; 168(3):228-36. PubMed ID: 9551108
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.